Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Nicholas Investment Partners LP

Nicholas Investment Partners LP lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 73.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,086 shares of the company's stock after selling 13,721 shares during the period. Nicholas Investment Partners LP's holdings in Krystal Biotech were worth $797,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of KRYS. Avanza Fonder AB bought a new stake in shares of Krystal Biotech in the 4th quarter valued at about $119,000. Crossmark Global Holdings Inc. boosted its holdings in shares of Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock worth $362,000 after buying an additional 121 shares during the period. Janney Montgomery Scott LLC grew its position in shares of Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company's stock valued at $8,239,000 after purchasing an additional 15,545 shares during the last quarter. Blue Trust Inc. increased its position in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after buying an additional 433 shares during the period. Finally, KBC Group NV raised its holdings in Krystal Biotech by 46.3% in the 4th quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after acquiring an additional 297 shares in the last quarter. 86.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. The trade was a 1.68% decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 6th. Guggenheim lowered their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Citigroup cut their target price on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday. Finally, Chardan Capital reissued a "buy" rating and issued a $219.00 price target on shares of Krystal Biotech in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $211.13.

Krystal Biotech Stock Up 0.3%

KRYS traded up $0.41 during midday trading on Tuesday, hitting $132.70. 43,471 shares of the company traded hands, compared to its average volume of 305,034. The firm has a market capitalization of $3.83 billion, a PE ratio of 44.25 and a beta of 0.79. The company's 50-day moving average is $165.82 and its 200 day moving average is $168.23. Krystal Biotech, Inc. has a 52 week low of $127.40 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. On average, sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).